AstraZeneca Recommends Shareholders Reject TRC Capital's Mini-Tender Offer - Quick Facts

AstraZeneca PLC (AZN.L,AZN) has received notification of an unsolicited mini-tender offer to holders of American Depositary Shares in AstraZeneca by TRC Capital Investment Corporation, which indicates that TRC Capital offers to purchase up to 2 million ADSs, equivalent to approximately 0.06% of the outstanding Ordinary Shares in AstraZeneca, at a price of $57.88 per ADS in cash. AstraZeneca recommended that shareholders reject the offer because the offer price is below the market price for ADSs.

Mini-tender offers are offers to purchase less than five percent of a company's outstanding shares.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT